PP405 is a new hair loss treatment facing mixed reactions due to initial hype and insufficient data. Some are hopeful, but many doubt its effectiveness compared to minoxidil and finasteride.
A user reported that Procerin, containing Saw Palmetto and Pumpkin seed oil, provided similar hair thickening results as finasteride but with milder side effects. They experienced reduced libido and watery ejaculations but are adjusting the dose to minimize these effects.
The conversation is about the interest in testing verteporfin, potentially with a dermaroller, for hair loss treatment. There is frustration over the lack of group buys for promising treatments compared to past efforts with less evidence.
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.
The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.
A user reports significantly reduced hair shedding by using a topical mixture containing 10% Minoxidil, 0.1% Melatonin, 5% Azelaic Acid, 5% Rosemary Oil, and 5% Peppermint Oil, and attributes the success mainly to Melatonin. They also use a copper peptide serum (AHK-Cu) for hair growth and Ketoconazole shampoo for scalp cleaning, but have stopped using other treatments like Finasteride and RU58841.
The user discusses a galenic hair lotion containing progesterone, estradiol, cyproterone, hydrocortisone butyrate, and cetirizine pheniramine, which has effectively stopped their hair loss over two years. They are curious about the compatibility of finasteride with the lotion's components and note that their trichologist has successfully used minoxidil and finasteride in similar treatments for others.
User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.
Investing in pharmaceutical products to treat hair loss and the potential risks associated with that, as well as other treatments such as Minoxidil, Finasteride, RU58841, and a COVID-19 booster.
Oleic acid, microneedling, and emu oil are discussed as potential hair growth treatments, with some users expressing skepticism about their effectiveness. Minoxidil and finasteride are recommended as current reliable treatments until more proven solutions are available.
PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.
An increase in libido associated with the use of Pyri, and a discussion about how it may be working comparably to other hair loss treatments such as RU58841, Finasteride and Minoxidil.
Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.
People are discussing hair loss treatments, including pyrilutamide, minoxidil, dutasteride, alfatradiol, and bimatoprost. Users share their experiences and side effects, noting that pyrilutamide is considered more effective and safer than RU58841.
A user is seeking help to purchase and ship Alpecin DMG to the United States due to issues with eBay sellers. They prefer Alpecin DMG over minoxidil because of concerns about minoxidil's effects on insulin production, as they have diabetes.
The conversation discusses using Minoxidil, finasteride, RU58841, and pyrilutamide for hair loss treatment. The user is considering adding a topical treatment and has not experienced side effects from current treatments.
Using Megatek with minoxidil significantly increases hair growth, especially vellus hairs, but is less effective alone. Biotin and ketoconazole shampoo are also used to support hair health.
The user is using a topical solution containing 1% finasteride and 5% minoxidil for hair loss, with water, glycerin, and PEG-40 hydrogenated castor oil as carrier agents. They are questioning if these ingredients are effective carriers after using the solution for three months.
The user resumed using topical finasteride after a two-week break and will update on side effects like water retention and gynecomastia in a month. They are also starting DIM and zinc.
Treatments for hair loss, such as Minoxidil, finasteride, RU58841 and Eucapil; the legitimacy of RU58841 products; and safety concerns related to using RU58841.
Hair loss discussion includes finasteride intolerance and questioning if Pyrilutamide is an alternative. Pyrilutamide not commercially available, but may be tolerable if approved since it's not a 5aR inhibitor.
PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.
Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.
The user is currently using finasteride and minoxidil and is considering adding microneedling and either RU58841 or Pyrilutamide for potential hair regrowth. They previously used microneedling, RU58841, and oral minoxidil before their hair transplant.
PP405 is expected to be a promising addition to hair loss treatments, potentially working well with existing treatments like finasteride and minoxidil, but not as a standalone solution. Users are hopeful for its effectiveness, especially in combination with other treatments, though expectations vary.
The user is considering adding Stemoxydine to their hair loss regimen, as they already use topical finasteride with rosemary and cannot use Minoxidil. They are seeking feedback on Stemoxydine and Alphatradiol, and another user mentions 2-deoxy-d-ribose as a potential option.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.